Could a probiotic pill improve vaginal health?
NCT ID NCT06830122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether taking a probiotic called Lactobacillus crispatus LCr86 by mouth could improve vaginal health in women with an intermediate vaginal microbiome. 80 women participated, taking either the probiotic or a placebo for 8 weeks. Researchers measured changes in vaginal bacteria scores, pH, and inflammation markers to see if the probiotic helped restore a healthy balance.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Lactobacillus crispatus LCr86 probiotic
- What this could lead to
- If successful, this could point toward a simple probiotic supplement to help restore healthy vaginal bacteria and reduce the risk of bacterial vaginosis.
- What could go wrong
- This is a small, completed trial with 80 participants. Results may not apply to all women, and the probiotic may not work for everyone. Long-term benefits are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
80 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 50 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Women of childbearing age over 19 years of age and under 50 years of age. 2. A person with a score of 4-6 on the Nugent core. 3. A person who agrees to participate in the human application test before the human application test begins and has prepared the written consent form. 4. A person who agrees to follow the contraception methods permitted by PI. Exclusion Criteria: 1. Those who are currently being treated for severe cardiovascular system, immune system, respiratory system, gastrointestinal tract/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease, tumor and malignant. 2. The subjects who treated for vaginal or urinary tract infection as of within 3 months (e.g., candidiasis, trichomonas infection, gonorrhea, chlamydial infection, etc.). 3. The subjects with vaginal or urinary tract bleeding, or abnormality. 4. The subjects who has been given antibiotics, antimicrobial agents, steroids, immunosuppressants, estrogen-based drugs (pneumonia-related drugs are allowed) within 4 weeks of visit 1 (but those who used them within 2 weeks of visit 1 cannot participate in the test). 5. The subjects who has consumed health functional foods related to improving immune function and vaginal health. 6. The subjects who has administered probiotics and prebiotics within two weeks based on visit 1 or has continuously administered or ingested fermented milk and lactobacillus products. 7. Allergic constitution or hypersensitivity to known components of the study drug. 8. The subjects who has received salivary treatment for sedimentation, women's cleansers, vaginal sanitizers, left fumigation, and vaginal health within two week of screening visit. 9. The subjects with unregulated hypertension (above 160mmHg or 90mmHg of blood pressure). 10. The subjects who AST (GOT) or ALT (GPT) is at least three times the normal limit of the testing agency. 11. The subjects who are sensitive or allergic to the ingredients of this human-applied test food. 12. Subjects who are pregnant, breastfeeding, or planning to conceive within three months. 13. If the daily alcohol intake is more than 20g. 14. Excessive smokers (≥20 pieces/day). 15. The subjects who has participated in another interventional clinical trial within three month of the commencement of this trial or who has a plan to participate in another interventional clinical trial (including a human application test) after the commencement of this human application test. 16. The subjects who is deemed inappropriate by the human application test testers for this human application test. 17. Other vaginitis: Trichomonas vaginalis (TV) infection or fungal infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Patients with bacterial vaginosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhao ruihang
Suzhou, Jiangsu, 215200, China